Navigation Links
Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine

CAMBRIDGE, England and CAMBRIDGE, Massachusetts, November 13 /PRNewswire-FirstCall/ --

- No Human Vaccine Currently Exists Against the West Nile Virus, Which has Caused 3,265 Cases and 92 Deaths in the US so far in 2007; Collaboration Aims to Bring Leading West Nile Virus Vaccine Candidate to Market as Rapidly as Possible

Acambis plc (Acambis) (LSE: ACM), a leading vaccine development company, announced today that it has signed an exclusive global collaboration agreement with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, for the development and marketing of Acambis' ChimeriVax(TM)-West Nile vaccine, which is the leading West Nile vaccine in development.

"Since 1999 when it was first detected in the US, the West Nile virus has spread across the entire continental United States, causing 27,240 cases and 1,054 deaths," commented Ian Garland, Chief Executive Officer of Acambis. "Vaccination is the ideal approach to tackling this disease and, through this unique collaboration, we aim to bring this vaccine to market as rapidly as possible."

"Providing a vaccine against West Nile disease may now be within reach. This vaccine candidate is the most promising in the industry and would help meet a growing public health need," said Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur.

Acambis started developing a West Nile vaccine in 1999, shortly after the virus was first identified in the US. Under the terms of the agreement, Acambis will continue to perform ChimeriVax(TM)-West Nile development activities, up to and including the filing of a license application in the US.

Acambis will receive an upfront payment of $10m in 2007 from Sanofi Pasteur, and would be eligible for pre- and post-marketing milestone payments of up to $70m based on product approval and sales in the US market. It would also be entitled to receive development funding and royalties on net sales of the vaccine. In addition, if the vaccine were registered in other countries, Acambis would be entitled to further post-marketing milestone payments and royalties.

There is currently no human vaccine for the prevention of West Nile virus-related disease and no specific treatment. As of 6 November 2007, 3,265 cases of disease and 92 deaths had been recorded in 42 US States by the US Centers for Disease Control and Prevention (CDC) this year. The CDC has identified those aged 50 and above as being most at risk of severe West Nile virus-related disease. In the US, this population totals more than 87 million people.

Acambis is currently conducting a Phase 2 safety, tolerability and immunogenicity trial of ChimeriVax-West Nile in the US in adults aged 41-64 years and 65 years and above. Preliminary data from a previous Phase 2 dose-ranging trial in healthy adults have shown that over 98% of subjects seroconverted 28 days after a single vaccination. The safety profile of the vaccine has been shown to be satisfactory. Acambis' West Nile vaccine candidate uses its proprietary ChimeriVax(TM) technology, which was developed in association with St Louis University.

About West Nile virus

West Nile virus is a potentially serious illness. Experts believe it is established as a seasonal epidemic in North America that flares up in the summer and continues into the fall. About one in 150 people infected with West Nile virus will develop severe illness. The severe symptoms can include high fever, headache, neck stiffness, stupor, disorientation, coma, tremors, convulsions, muscle weakness, vision loss, numbness and paralysis. These symptoms may last several weeks, and neurological effects may be permanent. Up to 20% of the people who become infected have symptoms such as fever, headache, body aches, nausea, vomiting, and sometimes swollen lymph glands or a skin rash on the chest, stomach and back. Symptoms can last for as short as a few days, though even healthy people have become sick for several weeks. Approximately 80% of people who are infected with West Nile virus will not show any symptoms at all.

About Acambis

Acambis is a leading vaccine company developing novel vaccines that address significant unmet medical needs or substantially improve standards of care. ChimeriVax(TM)-JE, Acambis' most advanced product in its non-biodefence pipeline, has to date shown an excellent safety and efficacy profile following pivotal Phase 3 trials. It is currently undergoing paediatric trials in India and is partnered with Sanofi Pasteur and Bharat Biotech. Acambis' proprietary ChimeriVax(TM) technology, developed in association with St Louis University, has also been used to develop ChimeriVax(TM)-West Nile, which is undergoing Phase 2 clinical testing, making it the most advanced investigational vaccine against the West Nile virus. Acambis has established a global collaboration with Sanofi Pasteur for further development and commercialization of the vaccine. ChimeriVax(TM) has also been applied to development of Sanofi Pasteur's tetravalent dengue vaccine, which has successfully demonstrated proof-of-concept in a Phase 2 trial by generating 100% seroconversion to all four dengue virus serotypes.

Acambis also has the only vaccine in development against Clostridium difficile bacteria, a leading cause of hospital-acquired infections. C. difficile is estimated to cause at least 350,000 cases of C. difficile-associated disease in the US alone with annual costs to the healthcare system of $1.1bn. Acambis' influenza program aims to develop a universal vaccine against influenza, for which a universal 'A' strain vaccine, ACAM-FLU-A, is currently being tested in a Phase 1 trial, and also includes various further vaccine candidates in the research and pre-clinical stages.

Acambis is recognised internationally as the leading producer of smallpox vaccines. Acambis' ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) vaccine for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection was licensed by the US Food and Drug Administration in August 2007. Acambis has manufactured doses of ACAM2000 for emergency-use stockpiles held by the US Government and several other governments around the world. For safety and prescribing information, please refer to

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at

"Safe Harbor" statement

Statements contained within this news release may contain forward-looking comments, which involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', or 'continue'. Predictions and forward-looking references in this news release are subject to the satisfactory progress of research which is, by its very nature, unpredictable. Forward projections reflect management's best estimates based on information available at the time of issue.



Ian Garland, Chief Executive Officer

Elizabeth Jones, Chief Financial Officer

Lyndsay Wright, VP, Communications and IR

Tel: +44-(0)1223-275-300


Jon Coles / Justine McIlroy / Margherita Lupi

Tel: +44-(0)20-7404-5959

SOURCE Acambis plc
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Richard Greco Joins Mediware Board
2. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
3. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
4. Dr. Mahesh Ramachandran Joins Marianjoy Medical Group
5. Nick Childs Joins Grey New York as Director of Content Development
6. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
7. David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager
8. NASN Joins Partnership to Fight Chronic Disease
9. AstraZeneca Joins Local Walking Movement
10. Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex
11. Fund Manager Joins Board of GSI Securitization Inc.
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology: